Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Compare

6,502 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VRTX Analyst Ratings

Moderate Buy

16 Buy

6 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Vertex

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$512.06

▲(11.51% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $512.06 with a high forecast of $604.00 and a low forecast of $414.00. The average price target represents a 11.51% change from the last price of $459.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"400":"$400","605":"$605","451.25":"$451.3","502.5":"$502.5","553.75":"$553.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":604,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$604.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":512.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$512.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":414,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$414.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[400,451.25,502.5,553.75,605],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.6,439.32307692307694,453.04615384615386,466.7692307692308,480.4923076923077,494.2153846153846,507.9384615384615,521.6615384615385,535.3846153846154,549.1076923076923,562.8307692307692,576.5538461538462,590.2769230769231,{"y":604,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.6,432.25076923076927,438.90153846153845,445.5523076923077,452.20307692307694,458.8538461538461,465.50461538461536,472.1553846153846,478.80615384615385,485.45692307692303,492.1076923076923,498.75846153846146,505.4092307692307,{"y":512.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,425.6,424.70769230769235,423.81538461538463,422.92307692307696,422.03076923076924,421.13846153846157,420.24615384615385,419.3538461538462,418.46153846153845,417.5692307692308,416.67692307692306,415.7846153846154,414.89230769230767,{"y":414,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":465.73,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":402.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":461.68,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":479.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":484.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":498.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.43,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":452.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":462.13,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":404.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":425.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$604.00

Average Price Target$512.06

Lowest Price Target$414.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Seigerman

BMO Capital

$530

Buy

15.42%

Upside

Reiterated

12/19/25

Vertex Pharmaceuticals: Strong Journavx Launch and Durable CF Franchise Underpin Buy Rating and Long-Term Growth Upside

Tazeen Ahmad

Bank of America Securities

$563→$571

Buy

24.34%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities

Louise Chen

Scotiabank

$495

Buy

7.79%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Scotiabank

Mohit Bansal

Wells Fargo

$460→$515

Buy

12.15%

Upside

Reiterated

12/10/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo

Myles Minter

William Blair

Buy

―

Reiterated

12/05/25

Vertex Pharmaceuticals Positioned for Blockbuster Success in Rare Disease Market with Strong Renal Franchise and Promising Clinical Data

Geoff Meacham

Citi

$575

Buy

25.22%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi

Salveen Richter

Goldman Sachs

$604

Buy

31.53%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals: Promising Advancements in Kidney Disease Treatments Drive Buy Rating

Terence Flynn

Morgan Stanley

$516→$564

Buy

22.82%

Upside

Upgraded

12/05/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Cory Kasimov

Evercore ISI

$475

Buy

3.44%

Upside

Reiterated

11/12/25

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Naz Rahman

Maxim Group

Hold

―

Reiterated

11/11/25

Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Andrew Fein

H.C. Wainwright

$478

Buy

4.09%

Upside

Reiterated

11/10/25

Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development

Joon Lee

Truist Financial

Buy

―

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Dyadic International (DYAI), REPRO-MED Systems (KRMD)

Joseph Stringer

Needham

Hold

―

Reiterated

11/10/25

Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data

Gena Wang

Barclays

$414

Hold

-9.85%

Downside

Reiterated

11/10/25

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

Hold

―

Reiterated

11/09/25

Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Seigerman

BMO Capital

$530

Buy

15.42%

Upside

Reiterated

12/19/25

Vertex Pharmaceuticals: Strong Journavx Launch and Durable CF Franchise Underpin Buy Rating and Long-Term Growth Upside

Tazeen Ahmad

Bank of America Securities

$563→$571

Buy

24.34%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities

Louise Chen

Scotiabank

$495

Buy

7.79%

Upside

Reiterated

12/18/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Scotiabank

Mohit Bansal

Wells Fargo

$460→$515

Buy

12.15%

Upside

Reiterated

12/10/25

Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo

Myles Minter

William Blair

Buy

―

Reiterated

12/05/25

Vertex Pharmaceuticals Positioned for Blockbuster Success in Rare Disease Market with Strong Renal Franchise and Promising Clinical Data

Geoff Meacham

Citi

$575

Buy

25.22%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi

Salveen Richter

Goldman Sachs

$604

Buy

31.53%

Upside

Reiterated

12/05/25

Vertex Pharmaceuticals: Promising Advancements in Kidney Disease Treatments Drive Buy Rating

Terence Flynn

Morgan Stanley

$516→$564

Buy

22.82%

Upside

Upgraded

12/05/25

Vertex Pharmaceuticals: Strategic Diversification and Promising Pipeline Justify Buy Rating

Cory Kasimov

Evercore ISI

$475

Buy

3.44%

Upside

Reiterated

11/12/25

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

Naz Rahman

Maxim Group

Hold

―

Reiterated

11/11/25

Maxim Group Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Andrew Fein

H.C. Wainwright

$478

Buy

4.09%

Upside

Reiterated

11/10/25

Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development

Joon Lee

Truist Financial

Buy

―

Reiterated

11/10/25

Analysts' Top Healthcare Picks: Dyadic International (DYAI), REPRO-MED Systems (KRMD)

Joseph Stringer

Needham

Hold

―

Reiterated

11/10/25

Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data

Gena Wang

Barclays

$414

Hold

-9.85%

Downside

Reiterated

11/10/25

Barclays Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)

Paul Matteis

Stifel Nicolaus

Hold

―

Reiterated

11/09/25

Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month

xxx

Success Rate

16/20 ratings generated profit

Average Return

+2.96%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +2.96% per trade.

3 Months

xxx

Success Rate

21/29 ratings generated profit

Average Return

+6.97%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.41% of your transactions generating a profit, with an average return of +6.97% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

24/32 ratings generated profit

Average Return

+15.64%

reiterated a buy rating last month

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +15.64% per trade.

2 Years

xxx

Success Rate

27/31 ratings generated profit

Average Return

+26.46%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 87.10% of your transactions generating a profit, with an average return of +26.46% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VRTX has received 41 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. VRTX average Analyst price target in the past 3 months is 512.06.

Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $5.12 with a range of $4.46 to $5.78. The previous quarter’s EPS was $4.80. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $3.19B with a range of $3.10B to $3.35B. The previous quarter’s sales results were $3.12B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Stock Forecast FAQ

What is VRTX’s average 12-month price target, according to analysts?

Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 512.06.

What is VRTX’s upside potential, based on the analysts’ average price target?

Vertex Pharmaceuticals has 11.51% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VRTX a Buy, Sell or Hold?

Vertex Pharmaceuticals has a consensus rating of Moderate Buy which is based on 16 buy ratings, 6 hold ratings and 0 sell ratings.

What is Vertex Pharmaceuticals’s price target?

The average price target for Vertex Pharmaceuticals is 512.06. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $604.00 ,the lowest forecast is $414.00. The average price target represents 11.51% Increase from the current price of $459.21.

What do analysts say about Vertex Pharmaceuticals?

Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of VRTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

VRTX Analyst Ratings

VRTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vertex Pharmaceuticals

VRTX Analyst Recommendation Trends

VRTX Financial Forecast

VRTX Earnings Forecast

VRTX Sales Forecast

VRTX Stock Forecast FAQ

Detailed List of Analyst Forecasts